ns-2359 ns-2359 ns-2359 (gsk-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. it was under development by glaxosmithkline (gsk) as an antidepressant, but was discontinued in 2009 when phase ii clinical trials showed the drug was not effective and not well tolerated. the results did not support further effort by the company. ns-2359 was also in clinical trials for the treatment of adhd, phase ii having been completed in 2007. a phase i clinical trial exploring the effect of ns-2359 on cocaine-dependent individuals was completed in 2002. ns-2359clinical dataatc codenoneidentifiers iupac name (1r,2r,3s,5s)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-azabicyclooctane pubchem cid11408320unii76h76554pachemical and physical dataformulac15h19cl2nomolar mass300.22 g·mol−13d model (jsmol)interactive image smiles clc1ccc(cc1cl)c(c2coc)cc3nc2cc3 (verify)